SCHEMBL26380198

SCHEMBL26380198

COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Br)c(Nc2ccc3nccnc3c2NS(=O)(=O)C(C)C)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 11/20 0.61
▸ ALK Q9UM73 10/20 0.60
▸ INSR P06213 8/20 0.59
▸ IGF1R P08069 7/20 0.59
▸ PLK1 P53350 2/20 0.59
▸ BMPR1B O00238 2/20 0.59
▸ PLK4 O00444 2/20 0.59
▸ GAK O14976 2/20 0.59
▸ ERN1 O75460 2/20 0.59
▸ STK10 O94804 2/20 0.59
▸ ABL1 P00519 2/20 0.59
▸ LCK P06239 2/20 0.59
▸ FYN P06241 2/20 0.59
▸ FES P07332 2/20 0.59
▸ YES1 P07947 2/20 0.59
▸ HCK P08631 2/20 0.59
▸ ROS1 P08922 2/20 0.59
▸ FER P16591 2/20 0.59
▸ EPHA2 P29317 2/20 0.59
▸ LTK P29376 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26380892 0.93 EGFR (0.65) EGFRALKINSRIGF1RPLK1
SCHEMBL29785246 0.93 EGFR (0.65) EGFRALKINSRIGF1RPLK1
SCHEMBL25791514 0.92 ALK (0.59) EGFRALKINSRIGF1RPLK1
SCHEMBL26380204 0.91 EGFR (0.75) EGFR
SCHEMBL26380208 0.89 EGFR (0.76) EGFR
SCHEMBL26403741 0.87 EGFR (0.62) EGFRALKINSRIGF1RPLK1
SCHEMBL24073384 0.85 EGFR (0.65) EGFRALKINSRIGF1RPLK1
SCHEMBL26906933 0.85 EGFR (0.76) EGFRALKINSRIGF1RPLK1
SCHEMBL29904660 0.85 EGFR (0.76) EGFRALKINSRIGF1RPLK1
SCHEMBL22027940 0.85 EGFR (0.81) EGFRALKINSRIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310428-A1 EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF Hongyun Biotech Co., Ltd. (CN) 2023-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310428-A1 EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF EGFR, ERBB2, ERBB4 EGFR 1/4885ALK 58/4885INSR 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback